Patents Examined by Bruce R. Campell
-
Patent number: 7205160Abstract: Heterogeneous assays for different analytes in a single biological sample are performed simultaneously in a multiplexed assay that combines flow cytometry with the use of magnetic particles as the solid phase and yields an individual result for each analyte. The particles are distinguishable from each other by characteristics that permit them to be differentiated into groups, each group carrying an assay reagent bonded to the particle surface that is distinct from the assay reagents of particles in other groups. The magnetic particles facilitate separation of the solid and liquid phases, permitting the assays to be performed by automated equipment. Assays are also disclosed for the simultaneous detection of antibodies of different classes and a common antigen specificity or of a common class and different antigen specificities.Type: GrantFiled: July 11, 2005Date of Patent: April 17, 2007Assignee: Bio-Rad Laboratories, Inc.Inventors: Michael I. Watkins, Richard B. Edwards
-
Patent number: 7205013Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: GrantFiled: October 25, 2004Date of Patent: April 17, 2007Assignee: MedImmune Vaccines, Inc.Inventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant
-
Patent number: 7204989Abstract: A highly immunoreactive viral peptide, pE2, is disclosed which is derived from the carboxy-terminal end region of ORF2 region of the hepatitis E virus (HEV) genome. A unique feature of the novel pE2 peptide is that it possesses conformational antigenic determinants which are only exposed when monomers of the peptide associate with one another through non-covalent interactions to naturally form homodimers. The novel pE2 peptide is proven to be highly reactive with sera from patients having current or past infection with HEV which suggests that the homodimer may mimic certain structural features of the HEV capsid protein. Furthermore, the antigenic activity of the pE2 peptide is strictly conformational in nature and therefore, exhibits immunochemical reactivity only when the peptide exists in a dimeric form. Consequently, the antigenic activity is lost upon dissociation of the dimers, but the activity is restored when the monomers reassociate to form dimers.Type: GrantFiled: September 28, 2000Date of Patent: April 17, 2007Assignee: Yang Sheng Tang Company LimitedInventors: Hon Mun Ng, Stanley Im, Jizhong Zhang
-
Patent number: 7201904Abstract: The invention provides compositions containing HCV epitopes, which are recognized by cytotoxic T lymphocytes. Such polypeptides are used in prophylactic vaccines, immunotherapies, and assays to monitor the progress or success of immune interventions. The compositions are optimized to elicit an immune response in a genetically-diverse population of individuals.Type: GrantFiled: May 16, 2003Date of Patent: April 10, 2007Assignee: The General Hospital CorporationInventors: Georg Lauer, Kei Ouchi, Bruce D. Walker
-
Patent number: 7202354Abstract: The subject invention relates to a novel hepatitis B surface antigen mutant and methods of detecting this mutant, and/or antibodies thereto, in patient samples. In particular, the mutant contains a substitution of amino acid threonine for the amino acid alanine at position 123 in the amino acid sequence of the hepatitis B surface antigen (HBsAg) protein.Type: GrantFiled: March 30, 2001Date of Patent: April 10, 2007Assignee: Abbott LaboratoriesInventors: Paul F. Coleman, Isa K. Mushahwar
-
Patent number: 7202021Abstract: This application includes description of antibodies for specifically detecting prions of human origin and methods for detecting pathogenic prions. In some embodiments, the antibodies bind to an epitope characteristic for a human prion protein which is not found in the prion proteins of other species. In some embodiments, the antibodies are not cross-reactive with cow, Syrian Gold hamster, mouse, or rat prions. The application also includes a conformation-dependent immunoassay method for detecting pathogenic prions in a sample containing a prion (PrP) protein. The PrP protein may be present in a first conformation and a second conformation, such as PrPC and PrPSc in which the two conformations have different binding affinity for the antibody used to detect them.Type: GrantFiled: October 18, 2002Date of Patent: April 10, 2007Assignee: Aventis Behring GmbHInventors: Martin Vey, Weigand Lang, Albrecht Groener, Anne Bellon
-
Patent number: 7198782Abstract: A method for efficiently searching novel physiologically active substances under a certain predictability. This searching method comprises, among receptors of cells producing an antagonist to a substance in vivo or receptors of cells producing an antagonist to the cells per se, finding a receptor having amino acid sequences of two or more sizes by comparing the cDNA sequences of the receptor, and then examining which region in the longer receptor is missed in the shorter receptor by comparing the above cDNA sequences. By using this method, remedies for diabetes comprising a peptide having the amino acid sequence represented by SEQ ID NO:1 or 5, insulin production regulators comprising a peptide having the amino acid sequence represented by SEQ ID NO:2, and gastric secretion inhibitors comprising a peptide having the amino acid sequence represented by SEQ ID NO:3 or 4 are provided.Type: GrantFiled: March 26, 2003Date of Patent: April 3, 2007Inventor: Kenji Sakamoto
-
Patent number: 7198783Abstract: The present invention relates to methods of sensitizing neoplastic cells to irradiation by using oncolytic viruses, particularly reoviruses. Also provided are methods of treating or ameliorating a tumor with a combination of oncolytic viruses and radiotherapy.Type: GrantFiled: May 8, 2003Date of Patent: April 3, 2007Assignee: Oncolytics Biotech Inc.Inventors: Donald Morris, Matthew C. Coffey, Bradley G. Thompson, Douglas Ball
-
Patent number: 7198793Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: GrantFiled: March 8, 2005Date of Patent: April 3, 2007Assignee: Novartis AGInventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko
-
Patent number: 7198892Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8023 to 8235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.Type: GrantFiled: March 25, 2005Date of Patent: April 3, 2007Assignee: Common Services AgencyInventors: Peter Simmonds, Peng Lee Yap, Ian Hugo Pike
-
Patent number: 7196066Abstract: Methods of eliciting an immune response in a subject by administering one or more large genomic DNA fragments are provided. Also provided are methods of identifying sequences encoding antigenic polypeptides. Also provided are vaccine compositions comprising one or more large genomic DNA fragments.Type: GrantFiled: November 1, 2000Date of Patent: March 27, 2007Assignee: Powderject Vaccines, Inc.Inventors: William F. Swain, Lee K. Roberts, Lendon G. Payne, Ralph P. Braun
-
Patent number: 7196183Abstract: The present invention relates to genomic nucleotide sequences and amino acid sequences corresponding to the non-coding and coding region of a new type of HCV. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes sequences. Particularly, the present invention relates to said new HCV type sequences; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the 5? NCR, Core, the E1 and the NS5 regions of the new HCV type. These new HCV sequences are useful to diagnose the presence of HCV type genotypes or serotypes in a biological sample. Moreover, the availability of these new type-specific sequences can increase the overall sensitivity of HCV detection and should also prove to be useful for prophylactic and therapeutic purposes.Type: GrantFiled: August 29, 2002Date of Patent: March 27, 2007Assignee: Innogenetics N.V.Inventors: Erwin Sablon, Leen-Jan Van Doorn, Wim Quint
-
Patent number: 7195763Abstract: Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAVVEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.Type: GrantFiled: August 5, 2004Date of Patent: March 27, 2007Assignee: The Texas A & M Univerisity SystemInventors: Yi Xu, Magnus A. O. Hook
-
Patent number: 7196186Abstract: A plasmid DNA that encodes one or more antigenic genes operably linked to a promoter and a truncated retroviral 3? LTR exhibits both enhanced safety and acceptable efficiency of expression of antigenic proteins.Type: GrantFiled: January 14, 2004Date of Patent: March 27, 2007Assignee: Research Institute for Genetic and Human Therapy (R.I.G.H.T.)Inventors: Julianna Lisziewicz, Jianqing Xu, Franco Lori
-
Patent number: 7195885Abstract: The present invention includes an assay useful for identifying inhibitors of Hepatitis C virus (HCV) activity. Particularly, the present invention is directed to a dual HCV assay useful for high throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and the amount of cytotoxicity associated with that test compound. The present invention also includes compounds discovered using this assay, compositions containing such compounds and methods of treating Hepatitis C by the administration of such compounds. The present invention also includes reporter assays using enzymes associated with HCV RNA replication, as well as a cell line having ATTC Accession No. PTA-4583.Type: GrantFiled: August 12, 2003Date of Patent: March 27, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Min Gao, Julie A. Lemm, Donald R. O'Boyle, Peter Nower, Karen Rigat, Jin-hua Sun
-
Patent number: 7192715Abstract: Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease.Type: GrantFiled: October 24, 2001Date of Patent: March 20, 2007Assignee: Oklahoma Medical Research FoundationInventors: John B. Harley, Judith A. James
-
Patent number: 7193058Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: June 23, 2004Date of Patent: March 20, 2007Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 7192759Abstract: Novel means and methods are provided for the production of mammalian viruses comprising, infecting a culture of immortalized human cells with the virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium, and removing the virus-containing medium. The viruses can be harvested and be used for the production of vaccines. Advantages are that human cells of the present invention can be cultured under defined serum free conditions, and the cells show improved capability for propagating virus. In particular, methods are provided for producing, in cultured human cells, influenza virus and vaccines derived thereof. This method eliminates the necessity to use whole chicken embryos for the production of influenza vaccines. The method provides also for the continuous or batchwise removal of culture media. As such, the present invention allows the large-scale, continuous production of viruses to a high titer.Type: GrantFiled: November 26, 1999Date of Patent: March 20, 2007Assignee: Crucell Holland B.V.Inventors: Maria Grazia Pau, Alphonsus G. C. M. UytdeHaag
-
Patent number: 7193039Abstract: The present invention refers to the chemical synthesis and potentiality for application in several biochemical assays, of a potent agonist of the ?-melanocyte stimulating hormone (?-MSH), labeled with an amino acid-type paramagnetic spin probe (Toac, or 2,2,6,6-tetramethylpiperidine-1-oxyl-amino-4-carboxylic acid), valuable for use in electron spin resonance and fluorescence allowing biochemical-clinical investigation of relevant physiological roles of ?-MSH in animal organism. The referred analogue of the present invention, acetil-Toac0-(Nle4, DPhe7)-?-MSH, where (Nle4, DPhe7)-?-MSH is nominated commercially as Melanotan™ and although containing a non-natural compound in its structure such as Toac, maintained entirely its potent agonist potency.Type: GrantFiled: December 22, 2000Date of Patent: March 20, 2007Assignee: Conselho Nacional de Desenvolvimento Cientifico E Technologico-CNPQInventors: Clovis Ryuichi Nakaie, Simone Dos Reis Barbosa, Eduardo Maffud Cilli, Maria Tereza Lamy-Freund, Armando Siuiti Ito, Maria Aparecida Visconti, Ana Maria De Lauro Castrucci
-
Patent number: 7192580Abstract: The subject invention relates to viruses that are able to purge (reduce or eliminate) undesirable cells in a mixture of cells. Undesirable cells can include neoplastic cells, cells mediating graft-versus host diseases, and autoimmune cells. The subject invention also relates to the purging of undesirable cells from bone marrow or peripheral blood cell harvests in the treatment of mammals including cancer patients, transplant recipients, and patients with autoimmune disease.Type: GrantFiled: November 19, 2003Date of Patent: March 20, 2007Assignees: Wellstat Biologics Corporation, University of OttawaInventors: Harold L. Atkins, John C. Bell, Conrad J. Heilman, Jr., Brian D. Lichty, Robert M. Lorence, Michael S. Roberts, David F. Stojdl